Main Menu

WISER-P: Using software to measure bone disease on imaging for patients with prostate cancer   

Open to recruitment

What is the study about? 

WISER-P is investigating new imaging techniques to monitor prostate cancer which has spread to peoples’ bones.

Prostate cancer which has spread outside the prostate often affects peoples’ bones. People receiving treatment for prostate cancer have regular CT scans and specialist bone scans, to check how well their treatment is working. An MRI scan, combined with a new computer program, might be able to tell earlier than standard scans if a treatment is not working. This would allow people to stop receiving treatments that are not working for them sooner. 

WISER-P is comparing whether the new MRI technique is better at identifying when cancer in people’s bones is growing than the standard CT and bone scan techniques.
     

Who is included in the study?

WISER-P includes 126 people with advanced prostate cancer which has spread to their bones. Everyone who joins WISER-P will be about to start a new treatment for their cancer, they may have already received previous treatments. People will be invited to join the trial by doctors at ten NHS hospitals across the UK.

What does the study involve?

Everyone who joins WISER-P will be about to start a new treatment for their cancer. This would be the same treatment they would receive if they didn’t join the trial. 

To check how well the treatment is working, people will have either:

• Standard CT scans and bone scans
• MRI scans of the whole body

Scans will be done when participants join the trial and 8-9 weeks after starting their new treatment. 

The scans from before and during treatment will be compared to see if the treatment is working or if cancer has spread within participants’ bones. Plans to continue or change treatments will be decided by participants with their doctors, based on how well the treatment is working for them.

Participants have regular check ups during and after their treatment and we collect information about how they are getting on until the study is completed.

 

Further information for participants

Patient Information Sheet

Further information for healthcare professionals 

Protocol Summary

Contact details and regulatory information

Chief Investigator: Professor Dow-Mu Koh. The Royal Marsden NHS Trust.

ICR-CTSU scientific lead: Dr Nuria Porta

Trial management contact: [email protected]

Sponsor: The Institute of Cancer Research

Funding: National Institute for Health Research i4i (Invention for Innovation) Challenge Award 

 

Trial identifiers

REC reference: 23/NE/0034

CPMS ID: 55351

ISRCTN:ISRCTN54072577

 

Publications and presentations

There have been no presentations or publications to date

In this section

WISER-P trial documents (password protected)

Clinical trials

List of ICR-CTSU trials

Division of Clinical Studies

The division carries out or coordinates high-quality trials and translational research at both an early phase – typically to test new targeted drugs – and a later stage.

Find out more